Time to Buy Rigel Pharmaceuticals, Inc. (RIGL) After Today’s Significant Increase?

April 17, 2018 - By Nellie Frank

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Logo

Investors sentiment increased to 2.06 in 2017 Q4. Its up 0.67, from 1.39 in 2017Q3. It is positive, as 14 investors sold Rigel Pharmaceuticals, Inc. shares while 18 reduced holdings. 22 funds opened positions while 44 raised stakes. 127.13 million shares or 21.87% more from 104.32 million shares in 2017Q3 were reported.
Bancorporation Of Ny Mellon accumulated 748,963 shares. Northern Trust holds 0% or 1.74 million shares. State Board Of Administration Of Florida Retirement Systems reported 0% stake. Credit Suisse Ag has invested 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Tudor Invest Corporation Et Al holds 0.01% or 55,806 shares in its portfolio. Prelude Cap Mgmt Limited Liability Corp invested in 0% or 5,619 shares. Manufacturers Life The holds 0% or 115,304 shares. Goldman Sachs Grp Inc holds 0% or 469,037 shares. California State Teachers Retirement System holds 233,174 shares or 0% of its portfolio. Eam Invsts Lc has invested 0.24% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Vanguard Grp owns 6.22M shares or 0% of their US portfolio. Swiss Fincl Bank owns 0% invested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) for 229,600 shares. Great West Life Assurance Com Can holds 16,712 shares or 0% of its portfolio. Metropolitan Life Insurance reported 33,686 shares stake. New York-based Jpmorgan Chase has invested 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL).

The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a huge mover today! The stock increased 10.19% or $0.38 during the last trading session, reaching $4.11. About 1.88 million shares traded. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has risen 9.91% since April 17, 2017 and is uptrending. It has underperformed by 1.64% the S&P500.
The move comes after 9 months positive chart setup for the $605.69M company. It was reported on Apr, 17 by Barchart.com. We have $4.27 PT which if reached, will make NASDAQ:RIGL worth $24.23 million more.

Analysts await Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report earnings on May, 1. They expect $-0.18 earnings per share, down 38.46 % or $0.05 from last year’s $-0.13 per share. After $-0.18 actual earnings per share reported by Rigel Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Ratings Coverage

Among 6 analysts covering Rigel Pharmaceuticals (NASDAQ:RIGL), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Rigel Pharmaceuticals had 12 analyst reports since November 6, 2017 according to SRatingsIntel. H.C. Wainwright maintained Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) rating on Friday, January 19. H.C. Wainwright has “Buy” rating and $7.0 target. The firm has “Buy” rating given on Tuesday, March 6 by Cantor Fitzgerald. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has “Buy” rating given on Wednesday, March 7 by H.C. Wainwright. As per Tuesday, April 3, the company rating was maintained by H.C. Wainwright. BMO Capital Markets maintained the stock with “Buy” rating in Tuesday, November 7 report. As per Friday, February 2, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained the stock with “Buy” rating in Monday, December 11 report. The company was maintained on Wednesday, April 4 by Jefferies. The rating was initiated by Piper Jaffray with “Buy” on Thursday, December 21. The firm has “Buy” rating given on Monday, November 6 by H.C. Wainwright.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company has market cap of $605.69 million. The companyÂ’s clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It currently has negative earnings. It is also developing two oncology product candidates, which are in Phase I and Phase II.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: